Cheek Filler: The Seven FDA-Approved Options, and What Each One Had to Prove
Reviewed for medical accuracy against our Medical Review Board · Last updated 31 August 2026
Part of Dermal Fillers
Seven fillers hold an FDA approval for cheek augmentation or midface volume. Two more approvals mention the cheek and are not on this list, because they are for different problems: Sculptra is approved for fine lines and wrinkles in the cheek, and Bellafill for cheek acne scars. Neither is a volume approval, and counting them would make the number wrong.
The cheek has more approved options than any other region we have researched. It also has the clearest example of something that affects how you should read the phrase "newly FDA-approved".
The finding that matters most. The two oldest approvals had to prove the filler worked better than doing nothing. Every approval since 2021 only had to show the product was not much worse than a filler already on the market. The permitted margin is ten percentage points. And in one 2025 trial the new product scored 3.5 points lower than its comparator and was approved anyway, correctly, because that is what the standard allows.
The seven approved products
| Product | Approval | Date | Age | What it had to prove |
|---|---|---|---|---|
| Juvéderm Voluma XC | P110033 | Oct 2013 | 21+ | Better than no treatment |
| Restylane Lyft | P040024/S073 | Jul 2015 | 21+ | Better than no treatment |
| Restylane Lyft, by cannula | P040024/S101 | Nov 2018 | 21+ | Approval for the instrument itself |
| Restylane Contour | P140029/S032 | Jun 2021 | 21+ | Not worse than an existing filler |
| RHA 4 / RHA Dynamic Volume | P170002/S048 | Sep 2025 | 22+ | Not worse than an existing filler |
| Belotero Volume (+) | P250020 | May 2026 | 22+ | Not worse than an existing filler |
| saypha ChiQ | P250021 | Jun 2026 | 21+ | Not worse than an existing filler |
Three of those are original PMAs, meaning entirely new devices rather than an existing product gaining an extra indication: Voluma XC in 2013, and then Belotero Volume (+) and saypha ChiQ within a month of each other in 2026. If you have not heard of saypha, that is why. It is a Croma-Pharma brand and its US approval is weeks old at the time of writing.
Note the age column. Five say 21 and over. RHA 4 and Belotero Volume (+) say 22. A 21-year-old is outside the studied population for two of the seven, which is the sort of detail that never appears in a consultation.
What "FDA-approved" proved, and when it changed
Every approval here is real and every trial was properly run. But they did not all answer the same question, and the difference is not a technicality.
Voluma XC, 2013. A superiority trial against no treatment. 345 patients. At six months, 85.6% of treated patients (178 of 208) were responders, a difference of 46.7% over the untreated control group, p < 0.001. That is a product demonstrating it does something.
Restylane Lyft, 2015. Also superiority against no treatment, 200 patients.
Then the design changes. Restylane Contour in 2021, RHA 4 in 2025, and both 2026 approvals were all non-inferiority trials against an active comparator. A non-inferiority trial does not ask whether the product works better than nothing. It asks whether it falls short of an existing product by more than a pre-agreed margin.
saypha ChiQ's approval document states that margin: minus ten per cent. So a new filler may perform up to ten percentage points worse than an established one and still be approved as non-inferior.
And it is not hypothetical. RHA 4's primary endpoint at eight weeks, from its own approval document:
- RHA 4, 131 patients: 87.0% responders [95% CI 80.2 to 91.7]
- Comparator, 42 patients: 90.5% responders [95% CI 77.9 to 96.2]
- Difference: minus 3.5% [95% CI minus 12.4 to 9.9]
RHA 4 scored lower than the product it was tested against, and was approved. That is the standard working as designed, not a failure of it.
To be fair to the regulator and to the manufacturers: non-inferiority is a legitimate and widely used design. Once a class of product is established as effective, requiring every new entrant to beat a placebo or no-treatment arm has ethical and practical problems, and testing against the real alternative is arguably more useful. None of this suggests these are bad products.
The consumer conclusion is narrower, and true: "newly FDA-approved" is not a claim of superiority. For the three most recent cheek fillers it means "shown not to be much worse than something that already existed". If a clinic offers you the newest option on the basis that newer is better, the approval documents do not support that reasoning.
Six different scales, five different timepoints
For the fourth facial region running, every manufacturer measured with its own instrument.
| Product | Scale | Primary endpoint measured at |
|---|---|---|
| Voluma XC | MFVDS (Allergan) | Month 6 |
| Restylane Lyft | MMVS (Medicis) | Month 2 |
| Restylane Contour | MMVS (Medicis) | Month 3 |
| RHA 4 / Dynamic Volume | TMVDS (Teoxane) | Week 8 |
| Belotero Volume (+) | MCFAS (Merz) | Week 12 |
| saypha ChiQ | MVDSS | Week 24 |
So the published percentages differ in what was measured, how it was scored, and when. Voluma's 85.6% is a six-month figure on Allergan's scale against no treatment. saypha's Week 24 responder rate is on a different scale against an active comparator. Those two numbers cannot be lined up, and any page that ranks cheek fillers by their headline percentage is comparing measurements taken with different rulers at different times.
This is the same pattern we found under the eye, on the chin and in the temple. Across four regions and sixteen approvals, not one trial compared two fillers head to head on a shared scale with the aim of showing which is better.
The cannula needed its own approval
One entry in the table is not a product at all. In November 2018 the FDA approved the use of a small bore, blunt tip cannula with Restylane Lyft for cheek augmentation as a separate regulatory action, P040024/S101.
That is worth knowing because instrument choice is often presented as a matter of practitioner preference. In the cheek, for at least one product, it is part of the approved labelling. It is also the only one of the seven with no downloadable summary document, because only original PMAs and Panel Track supplements require one, and this was neither.
On whether needle or cannula gives a better result, the honest answer from this cluster is that it depends on the region and not on the instrument. In the temple, Restylane Contour's trial had the cannula ahead, 96.7% to 88.0%. Under the eye, Belotero's had the needle ahead, 87.4% to 73.7%. Our temple filler and under-eye filler pages set out both.
What cheek filler costs
No manufacturer publishes a patient price, and we do not publish figures we cannot source. What is reliable is the structure.
Cheek filler is sold by the syringe, and the midface generally needs more volume than the under-eye and often more than the chin, because it is a larger area treated on both sides. So the number that determines your bill is total millilitres across the course, not the price of one syringe. Ask for the expected total, and ask whether a touch-up is included or billed separately, since several of these trials had an optional touch-up built into the protocol.
The pricing patterns we verify on our city pages apply here as much as to Botox: who injects changes the rate, first-visit prices expire, and some clinics apply a minimum spend. One Denver practice publishes a 23 per cent premium for the physician over the nurse injector for the same product.
One thing to weigh that is specific to this region: the midface is where filler accumulation is most visible over years, because it is where the largest volumes go. Our guide to pillow face covers what the imaging evidence shows about how long filler actually persists.
What to ask before you book
- Which of the seven, and why that one? No trial has compared them, so a reason based on your anatomy is informative and "it's the newest" is not.
- Am I inside the approved age range? If you are 21, RHA 4 and Belotero Volume (+) are approved from 22.
- How many millilitres in total, and is a touch-up included? Several trial protocols allowed a touch-up. Find out whether your quote does.
- Needle or cannula, and what is your reason? For Restylane Lyft in the cheek, cannula use is specifically in the approved labelling.
- Do you keep hyaluronidase on site? All seven are hyaluronic acid and can be dissolved. Confirm the reversal agent is in the building.
If the volume you want is lower on the face, chin filler covers three approved products and a severity limit on two of them. If it is higher, our temple filler page covers the one region the FDA regulates hardest.
Frequently asked questions
How many fillers are FDA-approved for the cheeks?
Does a newer cheek filler mean a better one?
Which cheek filler is best?
Is there an age limit for cheek filler?
Should cheek filler be injected with a needle or a cannula?
Can cheek filler be dissolved?
Sources
Every figure on this page was read from the documents below rather than from a clinic or a manufacturer's marketing. They open in a new tab so you can check any claim here against its source.
- Summary of Safety and Effectiveness Data, P110033, Juvéderm Voluma XC, US Food and Drug Administration
- Summary of Safety and Effectiveness Data, P040024/S073, Restylane Lyft, US Food and Drug Administration
- Summary of Safety and Effectiveness Data, P140029/S032, Restylane Contour, US Food and Drug Administration
- Summary of Safety and Effectiveness Data, P170002/S048, RHA 4 and RHA Dynamic Volume, US Food and Drug Administration
- Summary of Safety and Effectiveness Data, P250020, Belotero Volume (+), US Food and Drug Administration
- Summary of Safety and Effectiveness Data, P250021, saypha ChiQ, US Food and Drug Administration
- Dermal fillers (soft tissue fillers), US Food and Drug Administration
Know the count before the quote. The unit count is half the bill, and a low per-unit rate recovered by a high unit count is the commonest way a deal is not one. How to tell.
Deciding which area, not how many units? Botox by facial area covers what each zone actually achieves, which four are FDA approved, and the things Botox cannot fix at all.
